J&J's Subcutaneous Amivantamab Shows 42% ORR in Head and Neck Cancer Trial

Johnson & Johnson (NYSE: JNJ) on May 31, 2026, said its subcutaneous amivantamab achieved a 42% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma. The data come from the ongoing Phase 1b/2 OrigAMI-4 study. The trial evaluated the bispecific antibody targeting EGFR and MET in a heavily pretreated population. Amivantamab's intravenous version is already approved for non-small cell lung cancer. The subcutaneous formulation is designed to shorten administration time and improve patient convenience. J&J plans to present detailed results at an upcoming medical conference and discuss next steps with regulators. Head and neck cancer represents a significant unmet need, with limited treatment options after first-line therapy failure. Safety data were consistent with the known profile of amivantamab, with no new safety signals reported, the company said.